The Ministry of Public Health of Tucumán, Argentina, is advancing a clinical research project to evaluate a therapeutic alternative derived from mesenchymal stem cells for treating chronic diabetic foot ulcers, according to official ministry announcements. Health Minister Luis Medina Ruiz met with stem cell researcher Luis Costas Pérez and representatives from the Economic Federation of Tucumán to establish the framework for the upcoming clinical trial.
Clinical Trial Focuses on Diabetic Foot Ulcers
The pilot study is a controlled, randomized clinical trial designed to assess the safety, efficacy, and potential benefits of a specialized cellular derivative in patients with type 2 diabetes. According to the Ministry of Public Health, the initial research phase targets diabetic foot ulcers, a severe complication that frequently leads to chronic wounds and potential amputations. Unlike therapies utilizing live cells, the evaluated product consists of a cell-derived compound designed to facilitate tissue regeneration while offering improved application control, as explained by Luis Costas Pérez, a Tucumán-born researcher based in Spain.
Public, Private, and Academic Collaboration
The project coordinates resources across the provincial public health system, the National University of Tucumán, and the Economic Federation of Tucumán, with backing from the provincial government under Governor Osvaldo Jaldo. María Peral de Bruno, research coordinator for the Ministry of Public Health and the National University of Tucumán, stated that the initiative positions the region at the forefront of regenerative medicine in South America. Health officials, including research director Diego Abdala and PRIS director Noellia Bottone, confirmed that patient evaluations will take place across designated public reference hospitals once protocols are finalized.
Future Implications for Complex Pathologies
Minister Luis Medina Ruiz emphasized that successful trial outcomes could establish Tucumán as a prominent hub for advanced biotechnology and open new research avenues for other complex medical conditions. The collaborative effort relies on local medical infrastructure, academic personnel, and international scientific cooperation coordinated with Costas Pérez’s research group in Spain. Subsequent phases of the research program will depend entirely on safety and efficacy data gathered during this initial randomized trial.
Related reading